Can-Fite BioPharma (CANF) Stock Price, News & Analysis

Company Overview

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102). Piclidenoson is being evaluated for the treatment of rheumatoid arthritis and psoriasis, with pivotal studies designed to demonstrate efficacy and safety in patients who have shown inadequate responses to existing therapies. Namodenoson is in clinical development for hepatocellular carcinoma and nonalcoholic steatohepatitis (NASH), conditions with limited treatment options and high unmet demand. Can-Fite’s pipeline also features earlier-stage programs aimed at expanding the application of its adenosine receptor technology across additional therapeutic areas.

Can-Fite conducts its clinical trials in multiple geographies, including North America, Europe and Israel, collaborating with leading research institutions and contract research organizations to ensure rigorous study design and execution. The company has entered into strategic partnerships and licensing agreements to facilitate development, regulatory filing and potential commercialization of its product candidates. These collaborations are intended to extend Can-Fite’s global reach and leverage external expertise to accelerate development timelines.

Under the leadership of Chief Executive Officer Pnina Fishman, Can-Fite has maintained a focused strategy on clinical advancement and regulatory engagement. The management team brings extensive experience in biopharmaceutical development, regulatory affairs and commercial strategy. Looking ahead, Can-Fite aims to complete late-stage trials for its lead candidates, pursue regulatory approvals, and explore additional indications for its adenosine receptor platform to deliver new treatment options for patients worldwide.

Key Stats

• Today's Range: $0.65 to $0.67
• 50-Day Range: $0.63 to $1.05
• 52-Week Range: $0.63 to $3.12
• Volume: 100,064 shs
• Average Volume: 205,004 shs
• Market Capitalization: $2.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.50
• Consensus Rating: Buy

Can-Fite BioPharma Stock Analysis - MarketRank™

Can-Fite BioPharma scored higher than 59% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Can-Fite BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Can-Fite BioPharma has a consensus price target of $14.50, representing about 2,107.0% upside from its current price of $0.66.

Amount of Analyst Coverage

Can-Fite BioPharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Can-Fite BioPharma are expected to grow in the coming year, from ($1.25) to ($0.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Can-Fite BioPharma is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Can-Fite BioPharma is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Can-Fite BioPharma has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.60% of the outstanding shares of Can-Fite BioPharma have been sold short.

Short Interest Ratio / Days to Cover

Can-Fite BioPharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Can-Fite BioPharma has recently decreased by 64.46%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Can-Fite BioPharma does not currently pay a dividend.

Dividend Growth

Can-Fite BioPharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.60% of the outstanding shares of Can-Fite BioPharma have been sold short.

Short Interest Ratio / Days to Cover

Can-Fite BioPharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Can-Fite BioPharma has recently decreased by 64.46%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Can-Fite BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.80% of the stock of Can-Fite BioPharma is held by insiders.

Percentage Held by Institutions

Only 21.00% of the stock of Can-Fite BioPharma is held by institutions.

CANF Stock Analysis - Frequently Asked Questions

How have CANF shares performed this year?

Can-Fite BioPharma's stock was trading at $1.6250 on January 1st, 2025. Since then, CANF stock has decreased by 59.6% and is now trading at $0.6570.

How were Can-Fite BioPharma's earnings last quarter?

Can-Fite BioPharma Ltd. (NYSE:CANF) issued its quarterly earnings results on Tuesday, November, 30th. The company reported ($1.90) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $1.00. The firm had revenue of $0.25 million for the quarter.

When did Can-Fite BioPharma's stock split?

Shares of Can-Fite BioPharma reverse split on the morning of Monday, January 9th 2023.The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Can-Fite BioPharma?

Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Can-Fite BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Can-Fite BioPharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Meta Platforms (META), Broadcom (AVGO), Novo Nordisk A/S (NVO) and Adobe (ADBE).

Company Calendar

• Last Earnings: 11/30/2021
• Today: 9/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:CANF
• CIK: 1536196
• Web: www.canfite.com
• Phone: 972-3-924-1114
• Fax: 972-3924-9378
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Can-Fite BioPharma: $14.50
• High Price Target: $18.00
• Low Price Target: $11.00
• Potential Upside/Downside: +2,110.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.93
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $560 thousand
• Price / Sales: 4.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.76 per share
• Price / Book: 0.37

Miscellaneous

• Outstanding Shares: 3,540,000
• Free Float: N/A
• Market Cap: $2.32 million
• Optionable: Not Optionable
• Beta: 1.06